Mineralys Therapeutics, Inc. Common Stock Net Assets
Mineralys Therapeutics, Inc. Common Stock net assets. Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has net assets worth $550.92 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($667.85 Million) and total liabilities ($116.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MLYS net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $550.92 Million |
| % of Total Assets | 82.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 129.41 |
Net Assets of Mineralys Therapeutics, Inc. Common Stock (2020–2025)
Net assets of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Mineralys Therapeutics, Inc. Common Stoc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual net assets of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. For live market cap and overall valuation, see Mineralys Therapeutics, Inc. Common Stoc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $646.69 Million | +238.13% |
| 2024-12-31 | $191.26 Million | -20.69% |
| 2023-12-31 | $241.15 Million | +561.37% |
| 2022-12-31 | $-52.27 Million | -128.00% |
| 2021-12-31 | $-22.93 Million | -537.34% |
| 2020-12-31 | $-3.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mineralys Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45356600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Mineralys Therapeutics, Inc. Common Stock Net Assets Breakdown (December 2025)
Mineralys Therapeutics, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.00% |
| Other Components | $1.10 Billion | 170.69% |
| Total Equity | $646.69 Million | 100.00% |
Mineralys Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Digiwin Software Co Ltd
SHE:300378
|
$1.41 Billion |
|
ROBEX Resources Inc
AU:RXR
|
$1.41 Billion |
|
BH Macro Limited
LSE:BHMG
|
$1.41 Billion |
|
Rumble Inc.
NASDAQ:RUM
|
$1.41 Billion |
|
Ellington Financial Inc.
NYSE:EFC
|
$1.41 Billion |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
$1.41 Billion |
|
AnaptysBio Inc
NASDAQ:ANAB
|
$1.41 Billion |
|
Daqo New Energy Corp ADR
NYSE:DQ
|
$1.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mineralys Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 191,257,000 to 646,693,000, a change of 455,436,000 (238.1%).
- Net loss of 154,651,000 reduced equity.
- Share repurchases of 243,000 reduced equity.
- New share issuances of 578,361,000 increased equity.
- Other factors increased equity by 31,969,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-154.65 Million | -23.91% |
| Share Repurchases | $243.00K | -0.04% |
| Share Issuances | $578.36 Million | +89.43% |
| Other Changes | $31.97 Million | +4.94% |
| Total Change | $- | 238.13% |
Book Value vs Market Value Analysis
This analysis compares Mineralys Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.67x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.78 | $15.99 | x |
| 2021-12-31 | $-4.60 | $15.99 | x |
| 2022-12-31 | $-10.12 | $15.99 | x |
| 2023-12-31 | $6.66 | $15.99 | x |
| 2024-12-31 | $3.94 | $15.99 | x |
| 2025-12-31 | $9.56 | $15.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mineralys Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.02x
- Recent ROE (-23.91%) is above the historical average (-24.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.07 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.12 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.57 Million |
| 2023 | -29.81% | 0.00% | 0.00x | 1.04x | $-96.01 Million |
| 2024 | -92.97% | 0.00% | 0.00x | 1.08x | $-196.94 Million |
| 2025 | -23.91% | 0.00% | 0.00x | 1.02x | $-219.32 Million |
Industry Comparison
This section compares Mineralys Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $550.92 Million | 0.00% | 0.21x | $1.41 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more